Drugs / Allo-RevCAR01-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05949125 | Jan 2024 → May 2027 expected | acute myeloid leukemia | AvenCell Europe GmbH | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allo-RevCAR01-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05949125 ↗ |
| Modality | Cell therapy | “The cellular component Allo-RevCAR01-T consists of an allogeneic human T-cell genetically multi-edited” NCT05949125 ↗ |
| Route | Intravenous | “Allo-RevCAR01-T will be administered as IV infusion on Treatment day 1.” NCT05949125 ↗ |